May 24, 2016 3:01 PM ET

Pharmaceuticals

Company Overview of Shantha Biotechnics Pvt. Ltd.

Company Overview

Shantha Biotechnics Pvt. Ltd., a biotech company, is engaged in the production and commercialization of vaccines against Hepatitis B, Tetanus, Diphtheria, Pertussis, Haemophilus influenza type b, and Cholera, as well as recombinant Erythropoietin. Its products are sold in India and internationally. The company was founded in 1993 and is based in Hyderabad, India. Shantha Biotechnics Pvt. Ltd. operates as a subsidiary of Sanofi.

3rd & 4th Floor

H.No 5-10-173

Fateh Maidan Road

Basheerbagh

Hyderabad,  500004

India

Founded in 1993

Phone:

91 40 6630 1000

Fax:

91 40 2323 4133

Key Executives for Shantha Biotechnics Pvt. Ltd.

Chief Executive Officer, Managing Director, Dierctor, Member of Share Transfer Committee and Member of Audit Committee
Age: 46
Founder, Chairman, Member of Share Transfer Committee, Member of Audit Committee and Member of Remuneration Committee
Age: 68
Chief Financial Officer and Company Secretary
Chief Operating Officer and Executive Director
Director, Member of Remuneration Committee, Chief Executive Officer of Sanofi Pasteur and President of Sanofi Pasteur
Age: 52
Compensation as of Fiscal Year 2015.

Shantha Biotechnics Pvt. Ltd. Key Developments

Sanofi Pasteur Announces Availability of ShanIPV Manufactured by Shantha Biotechnics

Sanofi Pasteur has announced the availability of ShanIPV, a new injectable, inactivated polio vaccine, or IPV, manufactured by its affiliate, Shantha Biotechnics, in Hyderabad, India. These first vaccine doses will be available to implement one dose of IPV in India's immunization schedule for all infants. Sanofi Pasteur and its affiliate Shantha Biotechnics will together produce most of India's IPV supply.

Shantha to Establish New Insulin Manufacturing Facility in India

Sanofi SA (France) subsidiary Shantha Biotechnics (India) announced on 29 January that it will be establishing a new insulin-production site in Telangana, India. The new facility will serve to manufacture Sanofi's human insulin product Insuman (recombinant human insulin). Sanofi has pledged an investment of INR 4.6 billion (USD 85.19 million) towards the facility and expects an annual production rate of 60 million Insuman cartridges in the first 2-3 years.

Shantha Launches Paediatric Pentavalent Vaccine, Shan5

Sanofi Pasteur launched Shan5, its paediatric pentavalent vaccine developed and manufactured by its Indian affiliate Shantha. It is a fully-liquid five-in-one vaccine that provides effective protection for children from six weeks of age against five diseases, diphtheria, tetanus, pertussis, Hib and hepatitis B. The launch of Shan5 vaccine received prequalification status from the World Health Organization (WHO) in April 2014. Shan5’s prequalification gives many more children in India access to the latest fully-liquid, 5-in-1 vaccine. Further, the prequalification helps Shan5 secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Shantha Biotechnics Pvt. Ltd., please visit www.shanthabiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.